Christopher E. Whitehead

1.4k citations

25 papers · 461 indexed · h-index 10

Impact in

Rehabilitation top 10%
- Wound Healing and Treatments
Molecular Biology
- Ubiquitin and proteasome pathways
- Heat shock proteins research

Papers in ⓘ

Rehabilitation 3
- Wound Healing and Treatments 3
Genetics 3

Co-authors: Alnawaz Rehemtulla (6 shared papers)M. Serghiou (2 shared papers)Dipankar Ray (4 shared papers)Aarif Ahsan (4 shared papers)Mukesh K. Nyati (4 shared papers)Theodore S. Lawrence (4 shared papers)Curt M. Breneman (2 shared papers)N. Sukumar (1 shared paper)
Journals: Cancer Research (6 papers)Neoplasia (3 papers)Journal of Burn Care & Research (2 papers)Neuro-Oncology (2 papers)Molecular Cancer Therapeutics (1 paper)
Partner nations: United States Ukraine United Kingdom

In The Last Decade

Christopher E. Whitehead

25 papers receiving 459 citations

Peers

Countries citing papers authored by Christopher E. Whitehead

Since Specialization

Citations

This map shows the geographic impact of Christopher E. Whitehead's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher E. Whitehead with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher E. Whitehead more than expected).

Fields of papers citing papers by Christopher E. Whitehead

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher E. Whitehead. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher E. Whitehead. The network helps show where Christopher E. Whitehead may publish in the future.

Co-authors

The 25 scholars most cited alongside Christopher E. Whitehead, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Christopher E. Whitehead Line = papers co-authored together Christopher E. Whitehead links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 25 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	KRAS Protein Stability Is Regulated through SMURF2: UBCH5 Complex-Mediated β-TrCP1 Degradation Neoplasia ·Shirish Shukla, Uday Sankar Allam, Aarif Ahsan, Guoan Chen, Pranathi M. Krishnamurthy, Katherine B. Marsh, Matthew Rumschlag, Sunita Shankar, Christopher E. Whitehead, Matthew J. Schipper, Venkatesha Basrur, Daniel R. Southworth, Arul M. Chinnaiyan, Alnawaz Rehemtulla, David G. Beer, Theodore S. Lawrence, Mukesh K. Nyati, Dipankar Ray	2014	78
2	Wild-type EGFR Is Stabilized by Direct Interaction with HSP90 in Cancer Cells and Tumors Neoplasia ·Aarif Ahsan, Susmita G. Ramanand, Christopher E. Whitehead, Susan M. Hiniker, Alnawaz Rehemtulla, William B. Pratt, Shruti Jolly, Christopher J. Gouveia, Kristy Truong, Carter Van Waes, Dipankar Ray, Theodore S. Lawrence, Mukesh K. Nyati	2012	73
3	2-Alkylamino- and alkoxy-substituted 2-amino-1,3,4-oxadiazoles—O-Alkyl benzohydroxamate esters replacements retain the desired inhibition and selectivity against MEK (MAP ERK kinase) Bioorganic & Medicinal Chemistry Letters ·Joseph S. Warmus, Cathlin Flamme, Lu Yan Zhang, Stephen D. Barrett, Alexander J. Bridges, Huifen Chen, Richard Gowan, Michael D. Kaufman, Judy Sebolt-Leopold, Wilbur R. Leopold, Ronald L. Merriman, Jeffrey F. Ohren, A.G. Pavlovsky, Sally Przybranowski, Haile Tecle, Heather Valik, Christopher E. Whitehead, Erli Zhang	2008	60
4	Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor Bioorganic & Medicinal Chemistry ·Marcian E. Van Dort, Stefanie Galbán, Hanxiao Wang, Judith S. Sebolt–Leopold, Christopher E. Whitehead, Hao Hong, Alnawaz Rehemtulla, Brian D. Ross	2015	44
5	Transferable atom equivalent multicentered multipole expansion method Journal of Computational Chemistry ·Christopher E. Whitehead, Curt M. Breneman, N. Sukumar, Margret Ryan	2003	42
6	Rehabilitation After a Burn Injury Clinics in Plastic Surgery ·M. Serghiou, April Cowan, Christopher E. Whitehead	2009	34
7	Destabilization of the Epidermal Growth Factor Receptor (EGFR) by a Peptide That Inhibits EGFR Binding to Heat Shock Protein 90 and Receptor Dimerization Journal of Biological Chemistry ·Aarif Ahsan, Dipankar Ray, Susmita G. Ramanand, Ashok N. Hegde, Christopher E. Whitehead, Alnawaz Rehemtulla, Yoshihiro Morishima, William B. Pratt, Yoichi Osawa, Theodore S. Lawrence, Mukesh K. Nyati	2013	29
8	Efficacy of an EGFR-Specific Peptide against EGFR-Dependent Cancer Cell Lines and Tumor Xenografts Neoplasia ·Aarif Ahsan, Susmita G. Ramanand, Ingrid L. Bergin, Lilli Zhao, Christopher E. Whitehead, Alnawaz Rehemtulla, Dipankar Ray, William B. Pratt, Theodore S. Lawrence, Mukesh K. Nyati	2014	28
9	A 12-Year Comparison of Common Therapeutic Interventions in the Burn Unit Journal of Burn Care & Research ·Christopher E. Whitehead, M. Serghiou	2009	18
10	Predictive quantitative structure retention relationship models for ion-exchange chromatography Chromatographia ·Cecilia B. Mazza, Christopher E. Whitehead, Curt M. Breneman, Steven M. Cramer	2002	17
11	A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance Nature Cancer ·Christopher E. Whitehead, Elizabeth K. Ziemke, Christy L. Frankowski-McGregor, Rachel Mumby, June Hee Chung, Jinju Li, Nathaniel Osher, Oluwadara Coker, Veerabhadran Baladandayuthapani, Scott Kopetz, Judith S. Sebolt–Leopold	2024	9
12	Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition Cancer Research ·Cara Abecunas, Christopher E. Whitehead, Elizabeth K. Ziemke, Douglas G. Baumann, Christy L. Frankowski-McGregor, Judith S. Sebolt–Leopold, Mohammad Fallahi‐Sichani	2022	6
13	Targeting DNA Repair and Survival Signaling in Diffuse Intrinsic Pontine Gliomas to Prevent Tumor Recurrence Molecular Cancer Therapeutics ·Monika Sharma, Ivana Barravecchia, Robert Teis, Jeanette Cruz, Rachel Mumby, Elizabeth K. Ziemke, Carlos E. Espinoza, Varunkumar Krishnamoorthy, Brian Magnuson, Mats Ljungman, Carl Koschmann, Joya Chandra, Christopher E. Whitehead, Judith S. Sebolt–Leopold, Stefanie Galbán	2023	4
14	Dimensions of European Heritage and Memory: a Framework Introduction Christopher E. Whitehead, Mads Daugbjerg, Susannah Eckersley, Gönül Bozoğlu	2019	3
15	Special Considerations for Pediatric Burn Injuries Physical Medicine and Rehabilitation Clinics of North America ·Miranda Yelvington, Christopher E. Whitehead, Lori Turgeon	2023	2
16	Abstract 2931: MTX-211, a dual and selective inhibitor of EGFR and PI3 kinase, shows promising activity in combination with MEK inhibition in preclinical models of pancreatic cancer Cancer Research ·Christy L. Frankowski-McGregor, Joel D. Maust, Elizabeth K. Ziemke, Rachel Mumby, Amy M. Delaney, Alnawaz Rehemtulla, Christopher E. Whitehead, Judith S. Sebolt–Leopold	2018	2
17	Abstract 2764: Effect of PNT2258 combinations with docetaxel, dacarbazine, or vemurafenib on the A375 melanoma xenograft Cancer Research ·Wendi V. Rodrigueza, Christopher E. Whitehead, Ramzi M. Mohammad, J. Patrick McGovern, Michael J. Wick, Drew Rasco, Anthony W. Tolcher, Charles L. Bisgaier	2012	2
18	THER-29. NOVEL DUAL EGFR/PI3-KINASE INHIBITORS SHOW ENHANCED POTENCY, STRONGER PATHWAY SUPPRESSION AND TARGETING OF METABOLIC PROPERTIES IN PEDIATRIC AND ADULT HIGH GRADE GLIOMA MODELS THAN SINGLE KINASE INHIBITORS Neuro-Oncology ·Yusha Sun, Cavan P. Bailey, Christopher E. Whitehead, Judith S. Sebolt–Leopold, Joya Chandra	2019	2
19	Abstract 148: A dual and selective small molecule inhibitor of EGFR and PI3 kinase shows promising preclinical activity against KRAS and BRAF mutant colorectal tumors Cancer Research ·Joel D. Maust, Elizabeth K. Ziemke, Christy L. Frankowski-McGregor, Jun Beom Ku, Rachel Mumby, Karin M. Hardiman, Christopher E. Whitehead, Judith S. Sebolt–Leopold	2017	2
20	Synthesis and SAR development of PD 0325901, a potent and highly bioavailable MEK inhibitor. Cancer Research ·Michael D. Kaufman, Stephen D. Barrett, Cathlin Flamme, Joseph S. Warmus, Yvonne Smith, Manoj Cheriyan, Luyan Zhang, Haile Tecle, Judith S. Sebolt–Leopold, Heather Valik, Richard Gowan, Keri Van Becelaere, Ronald L. Merriman, Sally Przybranowski, Jeffrey F. Ohren, Christopher E. Whitehead, Wilbur R. Leopold, Ellen M. Dobrusin, Alexander J. Bridges	2004	1

About Christopher E. Whitehead

Christopher E. Whitehead is a scholar working on Rehabilitation, Genetics, Molecular Biology, Oncology and Immunology, having authored 25 papers that have together received 461 indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (5 papers), PI3K/AKT/mTOR signaling in cancer (4 papers), Protein Degradation and Inhibitors (3 papers), Toxin Mechanisms and Immunotoxins (3 papers), Heat shock proteins research (3 papers), Burn Injury Management and Outcomes (3 papers), Lung Cancer Treatments and Mutations (3 papers) and Wound Healing and Treatments (3 papers). The work is most often cited by research in Rehabilitation (40 citations), Molecular Biology (291 citations), Oncology (112 citations), Organic Chemistry (77 citations) and Computational Theory and Mathematics (42 citations). Christopher E. Whitehead has collaborated with scholars based in United States, Ukraine and United Kingdom. Frequent co-authors include Alnawaz Rehemtulla, M. Serghiou, Dipankar Ray, Aarif Ahsan, Mukesh K. Nyati, Theodore S. Lawrence, Curt M. Breneman, N. Sukumar, William B. Pratt and Susmita G. Ramanand. Their work appears in journals such as Cancer Research, Neoplasia, Journal of Burn Care & Research, Neuro-Oncology and Molecular Cancer Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact